Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections
June 29, 2020 07:30 ET
|
Iterum Therapeutics plc
Sulopenem demonstrates superiority in treatment of patients with quinolone resistant pathogens Company to discuss NDA filing with FDA DUBLIN, Ireland and CHICAGO, June 29, 2020 (GLOBE NEWSWIRE)...
Iterum Therapeutics plc Announces Result of Proposal 8 at Annual General Meeting
June 15, 2020 16:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 15, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
June 03, 2020 09:50 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 03, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces Topline Results for a Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
June 01, 2020 08:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 01, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports First Quarter 2020 Financial Results
May 14, 2020 06:45 ET
|
Iterum Therapeutics plc
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors -- DUBLIN,...
Iterum Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
April 09, 2020 16:05 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, April 09, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)
March 31, 2020 07:00 ET
|
Iterum Therapeutics plc
Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO,...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
March 12, 2020 06:45 ET
|
Iterum Therapeutics plc
--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 19, 2020 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors
January 17, 2020 06:15 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...